Clinical trials: Leukoderma
Vitiligo
Assess the Long Term Efficacy and Safety of Ruxolitinib Cream in Participants With Vitiligo
The purpose of this study is to evaluate the duration of response following withdrawal of ruxolitinib cream (Cohort A vehicle group), safety and maintenance of response with continued use of ruxolitinib cream in participants who…
- Trial name
- NCT04530344
- Testing
- ruxolitinib, Vehicle
- Where
- 84 sites in United States, Bulgaria and 6 more
- Volunteers
- 458 people
- Sponsor
- Incyte Corporation
Visible Light Exposure on Healthy Back Skin
ANTIPIGMENTING OR DEPIMENTING EFFICACY UNDER PART OF VISIBLE LIGHT
The study intends to validate a protocol and define a positive reference to evaluate the efficacy of anti-pigmenting and depigmenting agents under part of visible Light exposures, between 400nm to 450nm.
- Trial name
- ACR_BIOVI_21-0 (NCT06945393)
- Testing
- Cosmetic topical products
- Where
- Romania
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- L'Oreal
Non-segmental Vitiligo
A Phase IIb Dose-ranging Study to Assess the Efficacy and Safety of GIA632 in Participants With Non-segmental Vitiligo
The main purpose of this multicenter, randomized, double-blind, placebo-controlled Phase 2b study is to investigate the safety and efficacy of GIA632 in participants with NSV and to identify the optimal dose to be promoted into…
- Trial name
- VITESS (NCT07431177)
- Testing
- GIA632
- Where
- 83 sites in United States, Argentina and 10 more
- Volunteers
- 210 people
- Sponsor
- Novartis Pharmaceuticals
Vitiligo
Assess the Efficacy and Safety of SHR0302 Ointment in Adult Patients With Vitiligo
The purpose of this study is to assess the efficacy and safety of SHR0302 ointment in adult patients with Vitiligo.
- Trial name
- NCT04774809
- Testing
- Low Dose SHR0302 Ointment BID, High Dose SHR0302 Ointment BID
- Where
- 16 sites in China
- Volunteers
- 75 people
- Sponsor
- Reistone Biopharma Company Limited
Vitiligo
Investigating Healthcare Disparities in Vitiligo
Vitiligo is an acquired, non contagious skin disorder characterised by depigmented patches of skin that may appear in a localised or very generalised distribution, and affecting 0.5-2.0% of the global population.There are…
- Trial name
- NCT06097494
- Testing
- No intervention
- Where
- United Kingdom
- Volunteers
- 39,374 people
- Sponsor
- Momentum Data
Vitiligo
Afamelanotide and Narrow-Band Ultraviolet B (NB-UVB) Light in the Treatment of Nonsegmental Vitiligo
The purpose of this study is to determine whether afamelanotide and narrow band UVB are effective in the treatment of non-segmental vitiligo (NSV).
- Trial name
- NSV (NCT01382589)
- Testing
- Afamelanotide, NB-UVB
- Volunteers
- 15 people
- Sponsor
- Clinuvel Pharmaceuticals Limited
Vitiligo, Melanoma (Skin)
Incidence of Melanoma and Non-melanoma Skin Cancer in People With Vitiligo
This study examines melanoma and nonmelanoma skin cancer in people diagnosed with vitiligo compared to matched controls.
- Conditions
- Vitiligo, Melanoma (Skin), Nonmelanoma Skin Cancer, Squamous Cell Carcinoma
- Trial name
- NCT04969419
- Testing
- Exposure of skin cancer of interest
- Where
- United Kingdom
- Volunteers
- 75,771 people
- Sponsor
- Momentum Data
Vitiligo, Piebaldism
Evaluation of Non-cultured Epidermal Cellular Grafting vs Hyaluronic Acid for Repigmenting Vitiligo and Piebaldism
The purpose of this study is to assess the efficacy of autologous epidermal cells suspension grafting using a newly developed device named VITICELL® compared to placebo.
- Trial name
- NCT02156427
- Testing
- VITICELL
- Where
- 5 sites in Belgium, France and 1 more
- Volunteers
- 38 people
- Sponsor
- Laboratoires Genévrier
Vitiligo
Efficacy & Tolerance of Cosmetic Product RV5098A on Face Pigmentation Maintenance in Adult Vitiligo Patients.
Vitiligo is an autoimmune depigmentation disorder affecting 0.5 to 1% of the population worldwide. Vitiligo lesions are characterized by a progressive loss of pigmentation caused by the disappearance of functioning melanocytes in…
- Trial name
- NCT06446063
- Testing
- Test product, Control Product
- Where
- France
- Volunteers
- 19 people
- Sponsor
- Pierre Fabre Dermo Cosmetique
Vitiligo
A Study to Evaluate the Efficacy of Microneedling as a Stand-alone Treatment for Vitiligo
This is a study that is being conducted in order to assess the efficacy of microneedling as a stand-alone treatment for vitiligo.
- Trial name
- NCT05053022
- Testing
- Skinpen Precision System
- Where
- United States
- Volunteers
- 13 people
- Sponsor
- Crown Laboratories, Inc.
Vitiligo
Repigmentation of Stable Vitiligo Lesions Using Spray-On Skin™ Cells
To evaluate repigmentation and quality of life after treatment of stable vitiligo lesions using the RECELL Device.
- Trial name
- TONE (NCT05971381)
- Testing
- RECELL® Autologous Cell Harvesting Device
- Where
- 17 sites in United States
- Volunteers
- 109 people
- Sponsor
- Avita Medical
Vitiligo
Afamelanotide and Narrow-Band Ultraviolet B (NB-UVB) Phototherapy in the Treatment of Nonsegmental Vitiligo (NSV)
The purpose of this study was to evaluate the efficacy and safety of afamelanotide, when combined with narrowband ultraviolet B (NB-UVB) phototherapy, in patients with nonsegmental vitiligo.
- Trial name
- NCT04525157
- Testing
- Afamelanotide
- Volunteers
- 21 people
- Sponsor
- Clinuvel Pharmaceuticals Limited
Solar Lentigo
CLINICAL INVESTIGATION TO EVALUATE THE EFFICACY AND SAFETY OF EPILADY PROTOTYPE DEVICE FOLLOWED BY APPLICATION OF A TOPICAL FORMULA ON DEPIGMENTATION OF LENTIGO SPOTS
To assess the efficacy of the Epilady investigational device, used with and without a topical depigmenting formula, in reducing the appearance of lentigo spots on the hands and forearms of healthy female participants over an…
- Trial name
- EPILADY (NCT07239726)
- Testing
- LASER, LASER AND ACTIVE FORMULA
- Where
- Mauritius
- Volunteers
- 44 people, healthy volunteers welcome
- Sponsor
- Cosmetique Active International
Non-segmental Vitiligo
A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of VYN201 Gel in Subjects With Non-segmental Vitiligo.
The purpose of this study is to evaluate the efficacy, safety, and pharmacokinetics of VYN201 Gel in subjects with non-segmental vitiligo.
- Trial name
- NCT06493578
- Testing
- VYN201 Gel, Vehicle Gel
- Where
- 49 sites in United States, Canada
- Volunteers
- 205 people
- Sponsor
- Vyne Therapeutics Inc.
Alopecia Areata, Depressive Episode
The Epidemiology, Management, and the Associated Burden of Related Conditions in Alopecia Areata
This study series consists of four related studies and aims to explore and describe many important elements of alopecia areata over three key areas: (1) the current epidemiology of alopecia areata, (2) the prevalence and…
- Conditions
- Alopecia Areata, Depressive Episode, Recurrent Depressive Disorder, Anxiety Disorders
- Trial name
- NCT04239521
- Testing
- Exposure of interest (studies 2 & 3).
- Where
- United Kingdom
- Volunteers
- 51,955 people
- Sponsor
- Momentum Data
Alopecia Areata, Vitiligo
A Pilot Cohort Study of Risk Factors and Novel Methods of Skin Lesion Assessments in Adults With Atopic Dermatitis, Alopecia Areata, Psoriasis or Vitiligo
The objective of the study is to explore various clinical and biochemical parameters and their potential associations with disease severity, activity, and prognosis in atopic dermatitis, psoriasis, alopecia areata, and vitiligo.
- Conditions
- Alopecia Areata, Vitiligo, Atopic Dermatitis, Psoriasis
- Trial name
- Derma-001 (NCT06319781)
- Testing
- Observational
- Where
- 3 sites in Denmark
- Volunteers
- 370 people
- Sponsor
- Blueskin AS
Vitiligo
Phase II Clinical Trial of MH004 Ointment in Patients With Non-segmental Vitiligo
This is a multicenter, randomized, double-blind, vehicle-controlled phase II study of MH004 Ointment with a 28-week open-label long-term safety extension period.
- Trial name
- NCT07181187
- Testing
- MH004 Ointment, Vehicle Ointment
- Where
- China
- Volunteers
- 156 people
- Sponsor
- Minghui Pharmaceutical (Hangzhou) Ltd
Chronic Myelogenous Leukemia (CML), Metastatic Gastrointestinal Stromal Tumors (GIST)
Study to Allow Access to Nilotinib for Patients Who Are on Nilotinib Treatment in a Novartis-sponsored Study
The purpose of this study was to allow continued use of nilotinib in patients who were on nilotinib treatment in a Novartis-sponsored, Oncology Clinical Development \& Medical Affairs (CD\&MA) study and were benefiting from the…
- Conditions
- Chronic Myelogenous Leukemia (CML), Metastatic Gastrointestinal Stromal Tumors (GIST), Acute Lymphoblastic Leukemia (ALL), Receptor Tyrosine Kinase (KIT) Mutated Melanoma
- Trial name
- NCT01735955
- Testing
- Nilotinib
- Where
- 33 sites in United States, Austria and 14 more
- Volunteers
- 57 people
- Sponsor
- Novartis Pharmaceuticals
Vitiligo
A Proof of Concept, Phase 1 Study of CGB-600 for the Topical Treatment of Non-Segmented Facial Vitiligo
The goal of this clinical trial is to learn if drug CGB-600 works to treat vitiligo on the face and neck in participants between 18-60 years of age. It will also learn about the safety of CGB-600.
- Trial name
- NCT07357870
- Testing
- Drug: CGB-600 gel, experimental drug
- Where
- 2 sites in Turkey (Türkiye)
- Volunteers
- 36 people
- Sponsor
- CAGE Bio Inc.
Indolent Systemic Mastocytosis
Masitinib in Severe Indolent or Smoldering Systemic Mastocytosis
The objective of this study is to compare the safety and efficacy of masitinib (AB1010) to placebo in patients with mastocytosis with handicap.
- Trial name
- AB06006 (NCT00814073)
- Testing
- Masitinib, Best Supportive Care
- Where
- 24 sites in United States, France
- Volunteers
- 135 people
- Sponsor
- AB Science